Page 6 - Biocon

Stock calls by Sameet Chavan of Angel Broking: Sell Tata Motors, Biocon

One can see a formation of 'Bearish Engulfing' pattern on Tata Motors' daily chart

Tata Capital to pick minority stake in Biocon Biologics for $30 million

Equity infusion part of a larger $200-300 million round the company plans to raise over the next few months as it eyes an IPO

Itolizumab to be a blockbuster opportunity for Biocon: Kiran Mazumdar-Shaw

We felt that this was the drug that would actually have a role to play in dealing with the cytokine storm that is being seen in Covid-19 patients, says Shaw

MARKET WRAP: Sensex trims losses, ends 12 pts down; Nifty closes at 11,194

All that happened in the markets today

Market Ahead, July 24: All you need to know before the opening bell

Today, a total of 71 companies including ITC, Asian Paints, and Ambuja Cements are scheduled to announce their quarterly results

Biocon Q1 pre-tax profit declines 21% to Rs 252.30 crore, revenue up 14%

High R&D spend, low profitability in research services due to Covid-19 pull down net profit

Cheer in Covid times

Here's the backstory of Biocon's Alzumab which has been approved by the CDSCO for the treatment of Covid-19 in India

Sensex ends 269 pts up, Nifty tops 11,200; RIL m-cap crosses Rs 13.5 trn

All that happened in the markets today

Biocon diversifies business model, enters digital therapeutic segment

To launch Insulia for at-home management of diabetes in collaboration with Voluntis

Covid-19 treatment: A lowdown on possible cure and drugs being used

Business Standard takes a look at the common drugs that are being used in India for treating Covid-19 patients

Pharma industry steps up to cure black marketing of Covid-19 drugs

Some firms are now considering starting their own distribution centres in major cities

Plenty of catalysts for Biocon over the next few months, say analysts

Progress in biologics, projects in the pipeline driving prospects

Biocon eyes international markets to supply Itolizumab for Covid-19 therapy

Its partner Equillium is planning to carry out a clinical trial in the US, which could lead to huge spike in demand for the product

Biocon hits new high on DGCI nod to market Itolizumab for Covid treatment

Itolizumab will be manufactured and formulated as an intravenous injection at Biocon's bio-manufacturing facility at Biocon Park, Bengaluru

Biocon's drug Itolizumab gets regulator nod to treat Covid-19 patients

The drug which has got approval to treat moderate to severe Covid complications will be manufactured as an intravenous injection at Biocon's Bengaluru plant

Drug controller approves Biocon's psoriasis drug for emergency Covid-19 use

The firm presented the phase II clinical trial results to the drug regulator which were deliberated upon by the Subject Expert Committee of the DCGI's office

Pharma shares gain; Biocon, Granules hit record highs, Sun Pharma up 3%

At 10:27 am, Nifty Pharma index was up 1.5 per cent, as compared to 0.22 per cent decline in the benchmark Nifty50 index

Biocon to invest $200 million on capital expenditure in current fiscal

Biocon CEO and Managing Director Siddharth Mittal said the investment would be split across small molecules and biosimilar verticals

Biocon ties up with DKSH to distribute 7 products in Singapore, Thailand

Under the terms of the pact, DKSH will gain an exclusive license to register and commercialise the seven generic formulations from various therapeutic areas

Biocon gets a shot in the arm with FDA approval for insulin glargine

The drug will be major contributor in the firm's bid to reach $1 billion revenue target by FY22, says biologics CEO Hamacher